Scientific publications

Selection of relevant publications since 2008

  • 2021

    Intracellular Activity of Antibiotics against Coxiella burnetii in a Model of Activated Human THP-1 Cells
    F. Peyrusson, A. O. Whelan, M. G. Hartley, I. H. Norville, S. V. Harding, F. Van Bambeke
    Antimicrob Agents Chemother. 2021; 65(12)

    Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection
    I. Kerkez, P. M. Tulkens, T. Tenson, F. Van Bambeke, M. Putrins
    Antimicrob Agents Chemother. 2021, 65(12)

    Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
    M. G. Hartley, I. H. Norville, M. I. Richards, K. B. Barnes, K. R. Bewley, J. Vipond, E. Rayner, A. Vente, S. J. Armstrong, S.V. Harding
    Front. Microbiol. 2021; 10

    Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection
    K. B. Barnes, M. I. Richards, T. R. Laws, A. Nunez, J. E. Thwaite, C. Bentley, S. V. Harding
    Antimicrob Agents Chemother. 2021, 65(6) 

  • 2019

    The Fluoroquinolone Finafloxacin Protects BALB/c Mice Against an Intranasal Infection With Francisella tularensis Strain SchuS4
    K. B. Barnes, K. A. Hamblin, M. I. Richards, T. R. Laws, A. Vente, H. S. Atkins and S. V. Harding
    Front Microbiol. 2019; 10

    Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes
    H. Chalhoub, S. V. Harding, P. M. Tulkens and F. Van Bambeke
    Clin Microbiol Infect. 2019

    Demonstration of the Broad-Spectrum In Vitro Activity of Finafloxacin against Pathogens of Biodefence Interest
    K. B. Barnes, S. D. Zumbrun, S. A. Halasohoris, P. D. Desai, L. L. Miller, M. I. Richards, P. Russell, C. Bentley and S. V. Harding
    Antimicrob Agents Chemother. 2019; 63(12)

  • 2018

    Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates
    A. Vente, C. Bentley, M. Lückermann, P. Tambyah and A. Dalhoff
    Antimicrob Agents Chemother. 2018 Mar 27; 62(4)

    Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections
    F. M. E. Wagenlehner, M. Nowicki, C. Bentley, M. Lückermann, S. Wohlert, C. Fischer, A. Vente, K. Naber and A. Dalhoff
    Antimicrob Agents Chemother. 2018 Mar 27; 62(4)

    Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections
    M. Taubert, M. Lückermann, A. Vente, A. Dalhoff and U. Fuhr
    Antimicrob Agents Chemother. 2018 Mar 27; 62(4)

  • 2017

    Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance
    L. B. Randall, E. Georgi, G. H. Genzel and H. P. Schweizer
    J. Antimicrob Chemother. 2017 Apr; 72(4):1258–1260 

    Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei
    K. B. Barnes, K. A. Hamblin, M. I. Richards, T. R. Laws, A.Vente, H. S. Atkins and S. V. Harding
    Antimicrob Agents Chemother. 2017 Jun 27; 61(7)

    Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers
    M. Taubert, J. Chiesa, M. Lückermann, C. Fischer, A. Dalhoff and U. Fuhr
    Antimicrob Agents Chemother. 2017 Sep 22; 61(10)

    Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-ß-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections
    A. Dalhoff, S. Schubert and A. Vente
    Antimicrob Agents Chemother. 2017 Apr 24; 61(5)

  • 2015

    High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones
    J. W. Lee, N. Kim, R. H. Nam, J. M. Kim, J. Y. Park, S. M. Lee, J. S. Kim, D. H. Lee and H. C. Jung
    Antimicrob Agents Chemother. 2015 Dec; 59(12):7629–7636 

    Finafloxacin for the treatment of urinary tract infections
    R. Bartoletti, T. Cai, G. Perletti, F. M. E. Wagenlehner and T. E. Bjerklund Johanse
    Expert Opin Investig Drugs. 2015; 24(7):957-63 

  • 2014

    Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria
    G. H. Genzel, W. Stubbings, C. S. Stîngu, H. Labischinski and R. Schaumann
    Int J Antimicrob. 2014; 44:420–423 

  • 2011

    Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose
    F. M. E. Wagenlehner, C. M. Wagenlehner, B. Blenk, H. Blenk, S. Schubert, A. Dalhoff and K. G. Naber
    Chemotherapy 2011; 57:97–107

    In Vitro Spectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions
    W. Stubbings, P. Leow, G. C. Yong, F. Goh, B. Körber-Irrgang, M. Kresken, R. Endermann and H. Labischinski
    Antimicrob Agents Chemother. 2011 Sept; 4394–4397 

    Human Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers
    H. Patel, A. Andresen, A. Vente, H.-D. Heilmann, W. Stubbings, M. Seiberling, L. Lopez-Lazaro, R. Pokorny and H. Labischinski
    Antimicrob Agents Chemother. 2011 Sept; 55(9):4386-4393

    Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes
    E. A. Idelevich, A. Kriegeskorte, W. Stubbings, B. C. Kahl, G. Peters and K. Becker
    J Antimicrob Chemother. 2011; 66:2809-2813 

    Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila
    S. Lemaire, F. Van Bambeke and P. M. Tulkens
    Int J Antimicrob. 2011; 38:52–59 

    Comparative In Vitro Activities of the Novel Antibacterial Finafloxacin against selected Gram-Positive and Gram-Negative Bacteria Tested in Mueller-Hinton Broth and Synthetic Urine
    A. Dalhoff, W. Stubbings and S. Schubert
    Antimicrob Agents Chemother. 2011; 55:1814-1818 

  • 2010

    Activity of the Investigational Fluoroquinolone Finafloxacin against Ciprofloxacin-Sensitive and -Resistant Acinetobacter baumannii Isolates
    P. G. Higgins, W. Stubbings, H. Wisplinghoff and H. Seifert
    Antimicrob Agents Chemother. 2010; 54:1613-1615 

    Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance
    N.-C. Emrich, A. Heisig, W. Stubbings, H. Labischinski and P. Heisig
    J Antimicrob Chemother. 2010; 65:2530–2533

  • 2009

    The Lipopeptide Antibiotic Friulimicin B Inhibits Cell Wall Biosynthesis through Complex Formation with Bactoprenol Phosphate
    T. Schneider, K. Gries, M. Josten, I. Wiedemann, S. Pelzer, H. Labischinski and H.-G. Sahl
    Antimicrob Agents Chemother. 2009; 53:1610-1618 

    Daptomycin versus Friulimicin B: In-Depth profiling of Bacillus subtilis Cell Envelope Stress Responses
    T. Wecke, D. Zühlke, U. Mäder, S. Jordan, B. Voigt, S. Pelzer, H. Labischinski, G. Homuth, M. Hecker and T. Mascher
    Antimicrob Agents Chemother. 2009; 53:1619-1623

  • 2008

    Prospects and challenges in anti-infective research and development: new drugs and approaches.
    H. Labischinski and H. Ruebsamen-Waigmann
    Current Opinion in Pharmacology. 2008; 8(5):519-521